Please login to the form below
Ilumya
This page shows the latest Ilumya news and features for those working in and with pharma, biotech and healthcare.
AbbVie lauds head-to-head win for Skyrizi versus Cosentyx
Sun Pharmaceutical’s Ilumya (tildrakizumab) in recent years.
Latest news
-
Almirall eyes $62m takeover of multicytokine specialist Bioniz
Meanwhile, Almirall is in the launch phase for Ilumya/Ilumetri (tildrakizumab) for psoriasis, with ambitions to extend its use into eczema.
-
Latecomer Lilly preps its IL-23 drug for Crohn’s disease
Stelara has since been joined by J&J’s follow-up IL-23 inhibitor Tremfya (guselkumab), Sun Pharma’s Ilumya (tildrakizumab) and AbbVie/Boehringer Ingelheim’s Skyrizi (risankizumab), which are all
-
BMS psoriasis drug hits the mark in phase II
including Johnson &Johnson’s Stelara (ustekinumab) and follow-up Tremfya (guselkumab), Sun Pharma’s Ilumya (tildrakizumab) and AbbVie’s recently-filed risankizumab.
-
Sun Pharma passes milestone with novel psoriasis drug approval
Ilumya will treat adults with a moderate-to-severe form of the skin condition. ... We are committed to working with all relevant stakeholders to make Ilumya available to appropriate people with plaque psoriasis,” he added.
More from news
Approximately 1 fully matching, plus 4 partially matching documents found.
Subscribe to our email news alerts
- Contagious Conversations: Exploring Infectious Disease in the Digital Age
- Austrian State Secretary to speak at FlyPharma Europe 2023
- Further data for AstraZeneca/Daichii Sankyo’s Enhertu for breast cancer requested by NICE
- Gritstone Bio receives $433m BARDA contract for COVID-19 vaccine candidate
- EDX Medical Group develops multi-disease 'point-of-care' rapid tests for cancer, infections and cardiovascular conditions
- ScreenPoint Medical to showcase AI software at European scientific meeting
No results were found
PMHub
Twist Health
Not just another healthcare communications agency. We are a collection of award-winning industry experts focusing on bringing the very best...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
